[{"id":"01d5a833-1fd0-43f1-8b08-9b99a1ad4838","acronym":"","url":"https://clinicaltrials.gov/study/NCT05296278","created_at":"2022-03-26T00:54:56.650Z","updated_at":"2024-07-02T16:35:23.954Z","phase":"Phase 2","brief_title":"Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC","source_id_and_acronym":"NCT05296278","lead_sponsor":"Hunan Province Tumor Hospital","biomarkers":" ALK","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Alecensa (alectinib) • Lenvima (lenvatinib) • Yidafan (ivonescimab) • IBI-323 • simridarlimab (IBI-322)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/25/2023","start_date":" 12/25/2023","primary_txt":" Primary completion: 12/10/2025","primary_completion_date":" 12/10/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-01-10"}]